WCLC 2018 – Medical News Asia | Powered by ['mediPr]

JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

2 October 2018/0 Comments/in WCLC 2018, Lung Cancer, Oncology, Immunotherapy/by scienterrific

Avelumab (Bavencio®, Merck KGaA) does not improve the overall survival (OS) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-doublet chemotherapy, as resulted from the JAVELIN Lung 200 study (NCT02395172). The safety profile favoured avelumab over docetaxel.

Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

25 September 2018/0 Comments/in WCLC 2018, Lung Cancer, Oncology, Chemotherapy, Immunotherapy/by scienterrific

An interim analysis of the Phase III IMpower132 study showed that atezolizumab (Tecentriq®, Roche/Genentech) plus platinum-based chemotherapy (cisplatin or carboplatin) with pemetrexed improves the median progression-free survival (PFS) in treatment-naïve patients with non-squamous non-small cell lung cancer (NSCLC). The median PFS for atezolizumab plus pemetrexed and a platinum salt was 7.6 months vs 5.2 months with chemotherapy alone (HR=0.60, 95% CI: 0.49-0.72; p<0.0001).